Get the Stockscreener App
8.15
0.00%
0.00
After Hours:
8.15
Immunitybio Inc stock is traded at $8.15, with a volume of 9.33M.
It is up +0.00% in the last 24 hours and up +7.24% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.15
Open:
$8.24
24h Volume:
9.33M
Relative Volume:
0.38
Market Cap:
$8.54B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-20.91
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+5.03%
1M Performance:
+7.24%
6M Performance:
+291.83%
1Y Performance:
+227.31%
1-Day Range:
$7.922
$8.42
1-Week Range:
$7.58
$8.69
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.15 | 8.54B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ImmunityBio stock (US45258J1025): Class action deadline nears amid FDA scrutiny - AD HOC NEWS
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, - GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoil - MSN
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit S - GuruFocus
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - PR Newswire
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is 'almost there' - MSN
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
IBRX stock can't shake FDA delay overhang: Founder touts Saudi and Greece progress with Anktiva as bright spots - MSN
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered LossesContact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline - The Globe and Mail
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Loss - The National Law Review
IBRX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results - simplywall.st
ImmunityBio, Inc. (NASDAQ:IBRX) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
Immunitybio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IBRX Stock Can't Shake FDA Delay Overhang: Founder Touts Saudi And Greece Progress With Anktiva As Bright Spots - Stocktwits
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
Press releases provided by CNW - Techaeris
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Globe and Mail
Securities Class Action Deadline Against ImmunityBio, Inc. (NASDAQ: IBRX)Contact Kaplan Fox Before May 26, 2026 - The National Law Review
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
IBRX stock jumps after-hours: Bulls cheer 'unstoppable' global expansion amid US regulatory heat for Anktiva - MSN
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins ... - Caledonian Record
IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) - PR Newswire
IMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026 - The Globe and Mail
IBRX Lawsuit Alleges Company Allegedly Violated Drug - GlobeNewswire
FinancialContentIMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026 - FinancialContent
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):